0.7911
price down icon3.70%   -0.0304
after-market After Hours: .80 0.0089 +1.13%
loading
Allarity Therapeutics Inc stock is traded at $0.7911, with a volume of 1.11M. It is down -3.70% in the last 24 hours and down -11.81% over the past month. Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
See More
Previous Close:
$0.8215
Open:
$0.7717
24h Volume:
1.11M
Relative Volume:
0.43
Market Cap:
$3.51M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00384
EPS:
-206.0125
Net Cash Flow:
$-12.75M
1W Performance:
-23.93%
1M Performance:
-11.81%
6M Performance:
-55.05%
1Y Performance:
-83.99%
1-Day Range:
Value
$0.75
$0.82
1-Week Range:
Value
$0.75
$1.03
52-Week Range:
Value
$0.1131
$5.80

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name
Name
Allarity Therapeutics Inc
Name
Phone
401-426-4664
Name
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Name
Employee
6
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ALLR's Discussions on Twitter

Compare ALLR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALLR
Allarity Therapeutics Inc
0.7911 3.51M 0 -11.90M -12.75M -206.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Allarity Therapeutics Inc Stock (ALLR) Latest News

pulisher
09:01 AM

Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - stocksregister.com

09:01 AM
pulisher
Apr 03, 2025

Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Apr 01, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter

Mar 31, 2025
pulisher
Mar 26, 2025

Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire

Mar 25, 2025
pulisher
Mar 25, 2025

Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics probes potential stock manipulation - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan

Mar 24, 2025
pulisher
Mar 19, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Mar 19, 2025
pulisher
Mar 19, 2025

ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM

Mar 19, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity reports promising ovarian cancer trial results - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 14, 2025

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com

Mar 14, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures -March 13, 2025 at 09:18 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with SEC Over Previous Disclosures Regarding NDA for Dovitinib - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Settles SEC Probe: $2.5M Fine Won't Impact Clinical Trials or 2026 Outlook - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

SEC Says Ex-Allarity Execs Concealed Doomed FDA Approval - Law360

Mar 12, 2025
pulisher
Mar 10, 2025

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Grow - Asianet Newsable

Mar 10, 2025
pulisher
Mar 10, 2025

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN

Mar 10, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib and Temozolomide for Recurrent Small Cell Lung Cancer - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Can This Dual-Action Cancer Drug Overcome Previous PARP Inhibitor Limitations? - StockTitan

Mar 06, 2025
pulisher
Mar 05, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 30.0% in February - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

BDSX Shrinks Loss With Revenue Growth, ALLR Plans $5Mln Share Buyback, What's The Buzz At PTIX? - RTTNews

Mar 04, 2025
pulisher
Mar 04, 2025

Allarity Therapeutics (NASDAQ:ALLR) Board Authorizes Share Buyback Program - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Can Allarity's $5M Share Repurchase Signal Hidden Value in Its Cancer Treatment Pipeline? - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Allarity Board Authorizes Share Repurchase Program - Nasdaq

Mar 03, 2025
pulisher
Feb 27, 2025

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Legal Victory: How Allarity Therapeutics Defeated Its Securities Class Action Without Paying a Dime - StockTitan

Feb 26, 2025
pulisher
Feb 24, 2025

Allarity Therapeutics stock hits 52-week low at $0.87 By Investing.com - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

Allarity Therapeutics stock hits 52-week low at $0.87 - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can This New Ovarian Cancer Drug Challenge the $9B PARP Market? Complete Response Data Emerges - StockTitan

Feb 24, 2025

Allarity Therapeutics Inc Stock (ALLR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):